Axsome Therapeutics (AXSM) Stock Price

Axsome Therapeutics Price

NASDAQ·CLOSED
218.32USD+5.57 (+2.59 %)
Market closed

Over the last 4 years Axsome Therapeutics grew revenue by 191.7% annually, reaching 638.50 M USD. For Axsome Therapeutics, the net margin of -28.7% is up versus -1,530.0% a few years ago. The consensus 12-month price target for Axsome Therapeutics is 218.28 USD, about 0.0% below where the stock trades today. Of 26 analysts, 24 rate the stock a buy — an overall Buy consensus. The stock trades about 101% above its 52-week low.

Axsome Therapeutics stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Axsome Therapeutics over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Axsome Therapeutics stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Axsome Therapeutics's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Axsome Therapeutics Stock Price History
DateAxsome Therapeutics Price
8/10/2026218.32 USD
8/7/2026212.74 USD
8/6/2026210.13 USD
8/5/2026211.49 USD
8/4/2026211.98 USD
8/3/2026211.04 USD
7/31/2026217.99 USD
7/30/2026234.64 USD
7/29/2026230.99 USD
7/27/2026238.87 USD
7/23/2026241.53 USD
7/22/2026239.62 USD
7/21/2026236.95 USD
7/20/2026221.64 USD
7/17/2026230.00 USD
7/16/2026237.04 USD
7/15/2026237.53 USD
7/14/2026235.26 USD
7/13/2026229.25 USD
7/10/2026233.80 USD
7/9/2026248.95 USD
7/8/2026247.58 USD
7/7/2026249.76 USD
7/6/2026243.63 USD
7/2/2026244.31 USD
7/1/2026240.66 USD
6/30/2026244.77 USD
6/29/2026238.54 USD
6/26/2026241.67 USD
6/25/2026237.33 USD
6/24/2026237.92 USD
6/23/2026241.97 USD
6/22/2026248.41 USD
6/18/2026248.45 USD
6/17/2026251.76 USD
6/16/2026251.12 USD
6/15/2026254.00 USD
6/12/2026256.36 USD
6/11/2026253.15 USD
6/10/2026250.27 USD
6/9/2026245.64 USD
6/8/2026235.14 USD
6/5/2026234.54 USD
6/4/2026234.39 USD
6/3/2026225.16 USD
6/2/2026222.73 USD
6/1/2026230.19 USD
5/29/2026235.15 USD
5/28/2026235.05 USD
5/27/2026234.75 USD
5/26/2026235.67 USD
5/22/2026234.45 USD
5/21/2026231.04 USD
5/20/2026230.60 USD
5/19/2026226.67 USD
5/18/2026227.40 USD
5/15/2026227.72 USD
5/14/2026232.27 USD
5/13/2026235.32 USD
5/12/2026224.03 USD
5/11/2026216.47 USD
5/8/2026217.38 USD
5/7/2026220.22 USD
5/6/2026222.63 USD
5/5/2026223.06 USD
5/4/2026223.70 USD
5/1/2026206.53 USD
4/30/2026207.75 USD
4/29/2026183.95 USD
4/28/2026185.00 USD
4/27/2026187.40 USD
4/24/2026185.96 USD
4/23/2026182.72 USD
4/22/2026186.42 USD
4/21/2026182.97 USD
4/20/2026188.69 USD
4/17/2026188.99 USD
4/16/2026184.19 USD
4/15/2026184.18 USD
4/14/2026184.18 USD
4/13/2026178.33 USD
4/10/2026178.11 USD
4/9/2026178.90 USD
4/8/2026173.19 USD
4/7/2026168.74 USD
4/6/2026169.74 USD
4/2/2026168.51 USD
4/1/2026171.78 USD
3/31/2026169.02 USD
3/30/2026160.50 USD
3/27/2026156.35 USD
3/26/2026164.27 USD
3/25/2026161.78 USD
3/24/2026158.75 USD
3/23/2026156.84 USD
3/20/2026156.92 USD
3/19/2026158.88 USD
3/18/2026157.87 USD
3/17/2026161.17 USD
3/16/2026158.23 USD
3/13/2026156.08 USD
3/12/2026154.12 USD
3/11/2026159.50 USD
3/10/2026166.34 USD
3/9/2026164.49 USD
3/6/2026162.33 USD
3/5/2026161.46 USD
3/4/2026164.08 USD
3/3/2026164.05 USD
3/2/2026166.38 USD
2/27/2026163.89 USD
2/26/2026163.19 USD
2/25/2026164.22 USD
2/24/2026169.95 USD
2/23/2026174.76 USD
2/20/2026183.72 USD
2/19/2026186.18 USD
2/18/2026184.74 USD
2/17/2026183.30 USD
2/13/2026181.21 USD
2/12/2026182.94 USD
2/11/2026186.21 USD
2/10/2026184.30 USD
2/9/2026183.22 USD
2/6/2026182.55 USD
2/5/2026180.84 USD
2/4/2026185.54 USD
2/3/2026187.35 USD
2/2/2026185.88 USD
1/30/2026184.25 USD
1/29/2026185.27 USD
1/28/2026185.17 USD
1/27/2026188.02 USD
1/26/2026184.52 USD
1/23/2026185.96 USD
1/22/2026186.98 USD
1/21/2026189.10 USD
1/20/2026184.50 USD
1/16/2026177.27 USD
1/15/2026174.14 USD
1/14/2026177.01 USD
1/13/2026174.33 USD
1/12/2026176.82 USD
1/9/2026169.38 USD
1/8/2026167.55 USD
1/7/2026170.69 USD
1/6/2026171.88 USD
1/5/2026171.49 USD
1/2/2026178.69 USD
12/31/2025182.64 USD
12/30/2025148.79 USD
12/29/2025150.68 USD
12/26/2025152.05 USD
12/24/2025153.64 USD
12/23/2025154.19 USD
12/22/2025154.70 USD
12/19/2025152.65 USD
12/18/2025147.00 USD
12/17/2025148.00 USD
12/16/2025146.87 USD
12/15/2025146.24 USD
12/12/2025148.17 USD
12/11/2025148.75 USD
12/10/2025149.26 USD
12/9/2025145.22 USD
12/8/2025147.56 USD
12/5/2025149.22 USD
12/4/2025148.04 USD
12/3/2025147.81 USD
12/2/2025142.09 USD
12/1/2025149.03 USD
11/28/2025151.50 USD
11/26/2025150.98 USD
11/25/2025150.36 USD
11/24/2025151.20 USD
11/21/2025149.44 USD
11/20/2025143.31 USD
11/19/2025146.77 USD
11/18/2025147.48 USD
11/17/2025145.56 USD
11/14/2025139.69 USD
11/13/2025137.40 USD
11/12/2025140.86 USD
11/11/2025139.61 USD
11/10/2025137.80 USD
11/7/2025138.15 USD
11/6/2025139.41 USD
11/5/2025135.69 USD
11/4/2025134.93 USD
11/3/2025135.75 USD
10/31/2025134.99 USD
10/30/2025133.15 USD
10/29/2025133.33 USD
10/28/2025133.51 USD
10/27/2025134.68 USD
10/24/2025129.55 USD
10/23/2025127.06 USD
10/22/2025129.72 USD
10/21/2025131.39 USD
10/20/2025131.60 USD
10/17/2025127.94 USD
10/16/2025125.00 USD
10/15/2025129.58 USD
10/14/2025123.52 USD
10/13/2025121.15 USD
10/10/2025121.71 USD
10/9/2025122.52 USD
10/8/2025118.71 USD
10/7/2025118.64 USD
10/6/2025119.94 USD
10/3/2025120.30 USD
10/2/2025119.94 USD
10/1/2025118.57 USD
9/30/2025121.45 USD
9/29/2025117.62 USD
9/26/2025116.76 USD
9/25/2025116.01 USD
9/24/2025118.77 USD
9/23/2025118.19 USD
9/22/2025117.49 USD
9/19/2025115.95 USD
9/18/2025118.63 USD
9/17/2025116.62 USD
9/16/2025114.10 USD
9/15/2025116.78 USD
9/12/2025118.42 USD
9/11/2025122.96 USD
9/10/2025124.12 USD
9/9/2025125.68 USD
9/8/2025129.29 USD
9/5/2025125.17 USD
9/4/2025124.41 USD
9/3/2025122.00 USD
9/2/2025123.47 USD
8/29/2025121.28 USD
8/28/2025121.75 USD
8/27/2025121.86 USD
8/26/2025121.15 USD
8/25/2025116.31 USD
8/22/2025118.51 USD
8/21/2025117.14 USD
8/20/2025116.99 USD
8/19/2025111.29 USD
8/18/2025111.13 USD
8/15/2025109.21 USD
8/14/2025108.75 USD
8/13/2025109.39 USD
Access this data via the Eulerpool API
Get Free API Key

Axsome Therapeutics Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
270.60 M USD
-231.83 M USD
-239.24 M USD
Jan 1, 2024
385.69 M USD
-280.56 M USD
-287.22 M USD
Jan 1, 2025
638.50 M USD
-177.15 M USD
-183.17 M USD
Jan 1, 2026 (e)
974.07 M USD
-364.07 M USD
-125.39 M USD
Jan 1, 2027 (e)
1.57 B USD
-587.68 M USD
281.79 M USD
Jan 1, 2028 (e)
2.31 B USD
-858.52 M USD
739.50 M USD
Jan 1, 2029 (e)
3.12 B USD
-1.16 B USD
1.25 B USD
Jan 1, 2030 (e)
3.82 B USD
-1.42 B USD
1.60 B USD

Axsome Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 13, 2026, 7:36 AM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITB USD
EBIT MARGIN%
NET INCOMEB USD
NET INCOME GROWTH%
SHARESM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
––––––0.010.050.270.390.640.981.582.313.123.82
–––––––525.00440.0042.5965.7153.1361.5146.0735.4022.36
––––––-12.5088.0090.3791.4392.6392.6392.6392.6392.6392.63
0.590.590.590.590.590.59–0.040.240.350.590.911.462.142.893.54
-0.01-0.03-0.03-0.03-0.07-0.10-0.12-0.18-0.23-0.28-0.18-0.36-0.59-0.86-1.16-1.42
––––––-1,550.00-358.00-85.56-72.73-27.74-37.26-37.20-37.22-37.23-37.23
-0.01-0.03-0.03-0.03-0.07-0.10-0.13-0.19-0.24-0.29-0.18-0.120.260.741.251.60
100.00125.003.707.14126.6750.0031.3739.5527.8120.08-36.24-36.61-327.59179.9269.1527.84
14.4319.1524.2329.8734.7637.3537.7643.4547.3348.5450.6350.6350.6350.6350.6350.63
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Axsome Therapeutics generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Axsome Therapeutics retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Axsome Therapeutics's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Axsome Therapeutics has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Axsome Therapeutics's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Axsome Therapeutics stock margins

The Axsome Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Axsome Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Axsome Therapeutics.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
-13.10 %
-1,413.95 %
-1,530.01 %
Jan 1, 2022
89.61 %
-359.33 %
-373.99 %
Jan 1, 2023
90.37 %
-85.67 %
-88.41 %
Jan 1, 2024
91.37 %
-72.74 %
-74.47 %
Jan 1, 2025
92.56 %
-27.74 %
-28.69 %
Jan 1, 2026 (e)
92.56 %
-37.38 %
-12.87 %
Jan 1, 2027 (e)
92.56 %
-37.39 %
17.93 %
Jan 1, 2028 (e)
92.56 %
-37.23 %
32.07 %

Axsome Therapeutics Stock Revenue, EBIT, Earnings per Share

The Axsome Therapeutics earnings per share therefore indicates how much revenue Axsome Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
0.23 USD
-3.30 USD
-3.57 USD
Jan 1, 2022
1.15 USD
-4.14 USD
-4.31 USD
Jan 1, 2023
5.72 USD
-4.90 USD
-5.05 USD
Jan 1, 2024
7.95 USD
-5.78 USD
-5.92 USD
Jan 1, 2025
12.61 USD
-3.50 USD
-3.62 USD
Jan 1, 2026 (e)
19.32 USD
-7.19 USD
-2.49 USD
Jan 1, 2027 (e)
31.18 USD
-11.61 USD
5.59 USD
Jan 1, 2028 (e)
45.74 USD
-16.96 USD
14.67 USD

Axsome Therapeutics business model & stock analysis

Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of severe psychiatric and neurological disorders. The company was founded in 2012 and is headquartered in New York City. The history of Axsome Therapeutics began with the identification of a new molecule called AXS-05, which was developed as a potential antidepressant and treatment for Alzheimer's disease. The company utilized its proprietary technology platform to optimize the drug's properties and then began conducting clinical studies to evaluate the efficacy and safety of AXS-05 in patients with depression, Alzheimer's disease, and other neurological disorders. Axsome Therapeutics' business model is based on the identification and development of novel drug candidates through the use of knowledge about novel target molecules and innovative technologies. The company aims to rapidly and cost-effectively develop its drugs to quickly achieve commercial benefits from its developments. The company relies on collaboration with strategic partners and acquisitions for faster market entry. Axsome Therapeutics is divided into several business areas, each identifying and developing different drug candidates. For example, one area is the field of pain medicine, where the company is developing novel therapies for chronic pain and migraines. Another area is psychiatric disorders, where the company focuses on novel treatments for depression, anxiety disorders, bipolar disorder, and post-traumatic stress disorder. A third area is neurodegenerative diseases, where the company is researching new approaches to treating Alzheimer's disease and Parkinson's disease. Axsome Therapeutics has several products in the pipeline at various stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III clinical trials for the treatment of depression and Alzheimer's disease. AXS-05 has been deemed safe and well-tolerated in previous studies and has shown significant improvement in symptoms in patients with severe depression. In studies on Alzheimer's and dementia, the medication showed preliminary improvement in specific disease symptoms. In addition to AXS-05, the company is also working on the development of AXS-12, a drug for the treatment of narcolepsy, and AXS-09, a combination of two known drugs for the treatment of migraines. In summary, Axsome Therapeutics Inc. is a biopharmaceutical company focused on the development of novel therapies for the treatment of severe psychiatric and neurological disorders. The company has developed a proprietary technology platform that allows for cost-effective optimization and rapid development of drug candidates. Axsome Therapeutics is divided into several business areas and has several products in the pipeline at different stages of clinical development. The most advanced product is the antidepressant AXS-05, which is currently being tested in Phase III trials for the treatment of depression and Alzheimer's disease.

Axsome Therapeutics SWOT Analysis

Strengths

Axsome Therapeutics Inc has an impressive product pipeline that includes several innovative and potentially groundbreaking treatments. This provides a strong foundation for future growth and success in the pharmaceutical industry.

The company is led by a highly experienced and skilled management team, with a track record of success in the healthcare sector. Their expertise and strategic vision contribute to Axsome's ability to effectively navigate the competitive landscape.

Axsome's clinical trials have consistently demonstrated positive results, showing the efficacy and safety of their products. This not only boosts the confidence of investors and stakeholders but also contributes to gaining regulatory approvals more efficiently.

Weaknesses

Despite the company's promising product pipeline, Axsome currently has a limited market presence. This could potentially pose challenges in terms of market penetration and obtaining widespread adoption of their products.

Axsome's financial stability heavily relies on external funding sources, such as grants and partnerships. This dependence on external funding increases the vulnerability to market fluctuations and can pose obstacles to the company's plans for expansion and growth.

Opportunities

The pharmaceutical industry is witnessing a growing demand for innovative treatments, particularly in areas with high unmet medical needs. Axsome has the opportunity to capture this potential market by successfully commercializing their innovative products.

Axsome can explore strategic partnerships and collaborations with other pharmaceutical companies or research institutions. Such partnerships can provide access to additional resources, expertise, and distribution channels, facilitating faster market entry and expansion.

Threats

The pharmaceutical industry is highly competitive, with numerous established companies and new entrants constantly vying for market share. Axsome faces the threat of competition from larger, more resourceful competitors who may have similar products or better market access.

The regulatory landscape surrounding the pharmaceutical industry can be complex and stringent. Axsome might encounter challenges in obtaining necessary approvals from regulatory authorities, leading to potential delays or even rejection of their products.

Axsome's success heavily relies on the protection of their intellectual property rights. The company faces the risk of patent infringement and intellectual property theft, which could negatively impact their ability to generate revenue and maintain a competitive advantage.

Axsome Therapeutics Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Axsome Therapeutics Employees
Details
Date
Axsome Therapeutics Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Axsome Therapeutics Segments

Axsome Therapeutics Revenue by Segment

  • Max

Product
Royalty and Milestone Revenue
License
Details
Date
Product
Royalty and Milestone Revenue
License
Jan 1, 2024
381.68 M USD
4.02 M USD
0.00 USD
Jan 1, 2025
633.80 M USD
4.70 M USD
0.00 USD

Axsome Therapeutics Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Axsome Therapeutics historical P/E ratio, EBIT multiple, and P/S ratio

Axsome Therapeutics annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Axsome Therapeutics shares outstanding

The number of shares of Axsome Therapeutics was 50.63 M in 2025. This indicates how many shares Axsome Therapeutics is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
37.76 M Stocks
Jan 1, 2022
43.45 M Stocks
Jan 1, 2023
47.33 M Stocks
Jan 1, 2024
48.54 M Stocks
Jan 1, 2025
50.63 M Stocks
Jan 1, 2026 (e)
50.63 M Stocks
Jan 1, 2027 (e)
50.63 M Stocks
Jan 1, 2028 (e)
50.63 M Stocks

Current Axsome Therapeutics forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
4.39 %
Buy
92.31 % (24)
Hold
7.69 % (2)
Sell
0.00 % (0)
12M Price Target
218.28
Last Price
218.32
Currency
USD
12M Return Potential
-0.02 %
LTM Return
0 %

Axsome Therapeutics Analyst Rating Actions

DateFirmActionRatingReliability
7/15/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/8/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–
7/7/2026
RBC Capital
RBC Capital
MaintainedOutperform52
6/17/2026
TD Cowen
TD Cowen
MaintainedBuy60
5/5/2026
Wells Fargo
Wells Fargo
MaintainedOverweight56
5/5/2026
RBC Capital
RBC Capital
MaintainedOutperform52
5/5/2026
Needham
Needham
MaintainedBuy70
5/5/2026
Morgan Stanley
Morgan Stanley
MaintainedEqual Weight60
5/5/2026
Mizuho
Mizuho
MaintainedOutperform31
5/5/2026
HC Wainwright & Co.
HC Wainwright & Co.
MaintainedBuy–

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Axsome Therapeutics Earnings Calls

2025

Axsome Therapeutics Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.86USD-225.45 MUSD-2026 Q2
5/4/2026-0.89USD-195.32 MUSD-2026 Q1
2/23/2026-0.68USD-196.49 MUSD-2025 Q4
11/12/2024-1.44USD-100.06 MUSD-2024 Q3
5/6/2024-1.12USD-76.00 MUSD-2024 Q1
2/26/2024-1.22USD-67.81 MUSD-2023 Q4
11/6/2023-0.76USD-48.92 MUSD-2023 Q3
8/7/2023-0.92USD-38.17 MUSD-2023 Q2
5/1/2023-0.97USD-29.11 MUSD-2023 Q1
2/27/2023-1.09USD-23.35 MUSD-2022 Q4

EESG©

Eulerpool ESG Scorecard© for the Axsome Therapeutics stock

15/100
4
Environment
22
Social
18
Governance
E

Environment

20
Scope 1 - Direct Emissions—
Scope 2 - Indirect emissions from purchased energy—
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions—
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Axsome Therapeutics shareholder structure

% Name
7.76204%
BLACKROCK, INC.
BLACKROCK, INC.
4.08286%
VANGUARD PORTFOLIO MANAGEMENT LLC
VANGUARD PORTFOLIO MANAGEMENT LLC
3.84398%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
3.10850%
FMR LLC
FMR LLC
2.61269%
PRICE T ROWE ASSOCIATES INC /MD/
PRICE T ROWE ASSOCIATES INC /MD/
2.57425%
INVESCO LTD.
INVESCO LTD.
...

Axsome Therapeutics Beneficial Ownership Filings (SEC 13D/G)

Free Float
84.6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
15.00%
FMR LLC
FMR LLC
SEC ↗
15.00%
Edward C. Johnson 3d
Edward C. Johnson 3d
SEC ↗
15.00%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
10.00%
Select Biotechnology Portfolio
Select Biotechnology Portfolio
SEC ↗
8.20%
JPMorgan Chase & Co.
JPMorgan Chase & Co.
SEC ↗
7.07%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
6.90%
Roderick Wong
Roderick Wong
SEC ↗
5.60%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
5.50%
Iridian Asset Management LLC
Iridian Asset Management LLC
SEC ↗
5.50%
Harold J. Levy
Harold J. Levy
SEC ↗

Axsome Therapeutics Executives and Management Board

9 members · avg. age 54 · 11 % women

HT

Dr. Herriot Tabuteau (56)

Chairman of the Board, President, Chief Executive Officer, Founder · since 2012

10.36 M USD

Management

MJ

Mr. Mark Jacobson (41)

Chief Operating Officer

4.25 M USD
NP

Mr. Nick Pizzie (50)

Chief Financial Officer

3.76 M USD
HM

Mr. Hunter Murdock

General Counsel

3.25 M USD
AM

Mr. Ari Maizel (46)

Chief Commercial Officer

3.20 M USD

Board of Directors

MC

Dr. Mark Coleman (57)

Lead Independent Director

432,791.00 USD
MS

Mr. Mark Saad (55)

Independent Director

408,593.00 USD
RJ

Dr. Roger Jeffs (63)

Independent Director

403,734.00 USD
SM

Dr. Susan Mahony (60)

Independent Director

398,310.00 USD

Frequently asked questions about Axsome Therapeutics

The business model of Axsome Therapeutics Inc is focused on developing and commercializing innovative therapies for neurological disorders. The company aims to address unmet medical needs and improve the lives of patients by advancing its pipeline of potential treatments. Axsome Therapeutics Inc utilizes a strategic approach that includes clinical development, regulatory approvals, and collaboration with healthcare professionals and regulatory agencies. With a strong commitment to research and development, Axsome Therapeutics Inc seeks to provide effective therapies that can make a substantial impact in the field of neurology.

Axsome Therapeutics Inc is primarily active in the pharmaceutical industry.

The main competitors of Axsome Therapeutics Inc in the market include pharmaceutical companies such as Sage Therapeutics, Zosano Pharma Corporation, and Marinus Pharmaceuticals. Axsome Therapeutics Inc develops innovative treatments for central nervous system (CNS) disorders, focusing on difficult-to-treat conditions. With its unique product pipeline and research-driven approach, Axsome competes with these companies in developing novel therapeutics for CNS disorders.

Axsome Therapeutics Inc is a renowned biopharmaceutical company with a rich history and background. Founded in 2012, Axsome is dedicated to developing innovative therapies to improve the lives of patients suffering from central nervous system (CNS) disorders. The company focuses on areas such as depression, Alzheimer's disease, migraines, and other related conditions. Axsome Therapeutics Inc has a diverse pipeline of potential treatments and utilizes cutting-edge research and clinical trials to drive their drug development process. With a steadfast commitment to improving patient outcomes, Axsome Therapeutics Inc is emerging as a key player in the field of CNS therapeutics.

Axsome Therapeutics Inc has achieved several significant milestones. The company successfully received FDA approval for its product, which has shown promising results in clinical trials. Additionally, Axsome Therapeutics Inc has established strategic partnerships with key industry players and has expanded its product pipeline to target various medical conditions. Moreover, the company has successfully raised funding from renowned investors, enabling it to further advance its research and development efforts. Axsome Therapeutics Inc continues to make significant progress in the field of therapeutic treatments and is dedicated to improving the lives of patients.

Axsome Therapeutics Inc is primarily present in the United States.

Axsome Therapeutics Inc is a biopharmaceutical company focused on developing innovative therapies for central nervous system (CNS) disorders. The company's core values revolve around advancing the treatment options for patients suffering from CNS conditions such as major depressive disorder, Alzheimer's disease, and narcolepsy. Axsome Therapeutics Inc is committed to rigorous research and development to deliver breakthrough medicines that improve patients' lives. With a strong corporate philosophy centered on scientific excellence, patient-centricity, and a dedication to healthcare innovation, Axsome Therapeutics Inc aims to address unmet medical needs and make a lasting impact in the field of CNS disorders.

Analysts currently set an average price target of 217.31 USD for the Axsome Therapeutics stock (median: 218.28 USD), implying -0.5 % versus the latest price. The consensus is based on 26 analyst ratings.

Axsome Therapeutics Analyst Price Targets 2026

26 analysts currently rate the Axsome Therapeutics stock: 24 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Axsome Therapeutics to generate revenue of 974.07 M USD and earnings per share of -2.48 USD.

Axsome Therapeutics Analyst Price Targets 2026

Converted at the current exchange rate, the Axsome Therapeutics share trades at 189.28 EUR (218.32 USD).

The Axsome Therapeutics share (AXSM) is listed on 6 stock exchanges, including: NASDAQ (AXSM), Frankfurt (19X.F), München (19X.MU), Düsseldorf (19X.DU), London (0HKF.L), London (0HKF.L).

Axsome Therapeutics Inc is a publicly-traded biopharmaceutical company based in New York City that develops effective and safe therapies for patients with severe neurological disorders. The company primarily focuses on developing treatments for patients with depression, schizophrenia, Alzheimer's disease, fibromyalgia, and other serious neurological disorders. Axsome's business model is based on developing innovative therapies for patients that are currently not available on the market or have limited effectiveness. The company utilizes a combination of proprietary technologies and partnerships with leading academic institutions to develop these therapies. Axsome Therapeutics has focused on developing medications tailored to the needs of patients who cannot find appropriate treatment elsewhere. The company has successfully advanced its clinical development programs and demonstrated the potential to introduce new therapies for difficult-to-treat patients. Axsome Therapeutics has several products in clinical trials, including AXS-05, an NMDA receptor antagonist currently being developed for the treatment of depression and Alzheimer's disease. The company also has AXS-07, a new migraine medication, AXS-12 for the treatment of cataplexy in patients with narcolepsy, and AXS-14 for the treatment of fibromyalgia in clinical trials. To operate its business model successfully, Axsome Therapeutics utilizes a wide range of partnerships and distribution channels. The company works closely with academic centers and other industry leaders to evaluate and develop innovative solutions for difficult-to-treat patients. Additionally, Axsome Therapeutics collaborates with a number of strategic partners, including specialized CROs (contract research organizations) and distribution partners, to collect safety and efficacy data for its development programs and develop marketing strategies. Finally, Axsome Therapeutics also leverages the benefits of digital technologies to optimize its business model and improve access to its therapies. The company utilizes modern digital platforms to raise awareness among patients suffering from the diseases they treat about their clinical trials. This way, Axsome Therapeutics can potentially recruit more patients for their clinical trials and bring their therapeutics to market faster. In summary, Axsome Therapeutics Inc is an innovative biopharmaceutical company that focuses on developing therapies for difficult-to-treat diseases. The company utilizes a combination of proprietary technologies, strategic partnerships, and digital marketing to optimize its business model and successfully advance its development programs. With several products in clinical trials and a strong pipeline, Axsome Therapeutics is well-positioned to drive both patient well-being and company growth.

The expected revenue of Axsome Therapeutics is 974.07 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Axsome Therapeutics is -125.39 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Axsome Therapeutics is currently -88.15. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Axsome Therapeutics stock.

The price-to-sales ratio (P/S) of Axsome Therapeutics is currently 11.35. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Axsome Therapeutics stock.

The Eulerpool Quality Score for Axsome Therapeutics is 4/10.

The ISIN of Axsome Therapeutics is US05464T1043. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Axsome Therapeutics is A2AA7B. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Axsome Therapeutics is AXSM. The ticker symbol is used to trade Axsome Therapeutics shares on the stock exchange.

Axsome Therapeutics paid dividends every year for the past 0 years.

Axsome Therapeutics is assigned to the 'Health' sector.

The dividends of Axsome Therapeutics are distributed in USD.

All fundamentals and in-depth analysis of Axsome Therapeutics

Our stock analysis for Axsome Therapeutics stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Axsome Therapeutics. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Axsome Therapeutics Stock
Axsome Therapeutics Revenue→
Axsome Therapeutics Stock
Axsome Therapeutics Net Income→
Axsome Therapeutics Stock
Axsome Therapeutics P/E→
Axsome Therapeutics Stock
Axsome Therapeutics P/S→
Axsome Therapeutics Stock
Axsome Therapeutics EBIT→
Axsome Therapeutics Stock
Axsome Therapeutics Dividend→
Axsome Therapeutics Stock
Axsome Therapeutics Directors Dealings→
Axsome Therapeutics Stock
Axsome Therapeutics Stocks→
Axsome Therapeutics Stock
Axsome Therapeutics Market capitalization→
Axsome Therapeutics Stock
Axsome Therapeutics Debt→
Axsome Therapeutics Stock
Axsome Therapeutics Liabilities→
Axsome Therapeutics Stock
Axsome Therapeutics Equity→
Axsome Therapeutics Stock
Axsome Therapeutics AAQS→
Axsome Therapeutics Stock
Axsome Therapeutics Employees→
Axsome Therapeutics Stock
Axsome Therapeutics ROE→
Axsome Therapeutics Stock
Axsome Therapeutics ROA→
Axsome Therapeutics Stock
Axsome Therapeutics ROCE→
Axsome Therapeutics Stock
Axsome Therapeutics News→
Axsome Therapeutics Stock
Axsome Therapeutics Analyst Price Targets→

Health Stocks

Aytu BiopharmaAxoGenAYYAN Investment Co SJSCAxim BiotechnologiesAzitraAxe ComputeB-SOFT CoAvricore HealthBabylon HoldingsAvitarBACHEM HOLDINGAVITA MedicalAll Stocks A–Z →